Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07571746 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
A Phase 2 study, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT07571746 is a Phase 2 study that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 43 participants.
The verdict
NCT07571746, a Phase 2 study, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
Interventions
- DRUG Surovatamig
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2026-03-28 |
| Est. Completion | 2029-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07571746
The ClinicalTrials.gov registry entry for NCT07571746 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Surovatamig is the first listed.
NCT07571746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07571746 about?
NCT07571746 is a clinical study titled "A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease". The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and efficacy of surovatamig administered by subcutaneous injection in adult participants with primary membranous nephropathy.
What is the current status of trial NCT07571746?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2026-03-28. Estimated completion is 2029-10-15.
What interventions are being tested in trial NCT07571746?
The interventions under investigation include: Surovatamig (DRUG).
Who is sponsoring clinical trial NCT07571746?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.